Glenmark Pharmaceuticals Limited — Updates, 23-05-2025: Press Release

Glenmark Pharma has announced a board meeting to review the financial results for the quarter and half-year. FY25 revenue rose 12.8% to Rs. 13,321.7 Cr, led by strong growth in India (+31.9%) and Europe (+17.6%). Q4 revenue increased 6.3% YoY with stable EBITDA margin around 17.2%. North America sales declined 5.4% in Q4 but are expected to improve with upcoming respiratory and injectable product launches. The pipeline advanced as ISB 2001 secured FDA Fast Track status for multiple myeloma, supporting Glenmark’s oncology expansion through Ichnos Glenmark Innovation.